The Group earns revenues from a number of legacy non-inhaled products. As anticipated, revenue from non-inhaled products declined by 13.5% to £29.4m, following the expiry of certain patents for EXPAREL®, ADVATE®, and Xatral®.

Vectura received £5.1m in revenues from net sales of EXPAREL® during 2018.

Solaraze® royalties were £2.0m for 2018 (2017: £2.9m), a decline of 31.0%.

Transforming our oral manufacturing site in Lyon

Over the past two years, a significant transformation programme has taken place at Vectura’s Lyon oral manufacturing site. This has included the development of an end-to-end contract development and manufacturing organisation approach, ranging from early stage development, scale-up, and manufacturing through to bottling and blister line packaging, including serialisation and aggregation. As a result of these initiatives, along with significant operational KPI improvements, the site signed six new manufacturing and development contracts in 2018. These new agreements have enabled the site to increase development revenues by 25% which has largely offset the reduction in Sular® product supply revenue and has mitigated the impact of the expected decline of royalty revenues from legacy products.

Find out more on the Skyepharma website